Navigation Links
Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results
Date:4/14/2011

SHENZHEN, China, April 14, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. (OTC Bulletin Board: GPHG) ('Global Pharm" or the "Company"), a Shenzhen-based, leading vertically integrated pharmaceutical company engaged in pharmaceutical related products distribution business through its subsidiaries in Anhui, Jilin, and Shandong provinces, today reported financial results for the twelve months ended December 31, 2010.

Fiscal Year 2010 Highlights

  • Revenues increased 61.7% year-over-year to $140.3 million
  • Gross profit increased 64.5% year-over-year to $26.4 million with gross margin of 18.8%
  • Operating income increased 12.3% year-over-year to $15.9 million
  • Net income was $11.2 million, or $0.51 per diluted share, as compared to $10.9 million, or $0.57 per diluted share, in the same period last year
  • Adjusted net income, which excluded non-cash expenses related to share-based compensation for employees and merger costs, was $17.9 million, or $0.82 per diluted share

  • "We are pleased to announce record financial results for 2010, which continues to validate our strategy of building a solid distribution capacity and growing to become a major rapid-growing and profitable pharmaceutical company," stated Mr. Yunlu Yin, Chief Executive Officer of Global Pharm.

    Fiscal Year 2010 ResultsTotal Revenues for the twelve months ended December 31, 2010 increased by 61.7% to $140.3 million from $86.8 million in twelve months ended December 31, 2009.

    The strong year-over-year revenue growth was mainly attributable to increased sales in the Company's pharmaceutical products distribution business segment, which grew 65.0% year-over-year, and the herbal cultivation and sales business segment, which grew 105.2% year-over year.

    Below is a breakdown of sales per business segment for fiscal year 2010 a
    '/>"/>

    SOURCE Global Pharm Holdings Group, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. The American Chamber of Commerce in Spain Awards the Global Business Leader Award 2011 to Victor Grifols Roura, President and CEO of Grifols
    2. Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL
    3. Reportlinker Adds Quantum Dots: Technologies and Global Markets
    4. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
    5. Reportlinker Adds Global Nanobiotechnology Industry
    6. Reportlinker Adds Global Biochips Industry
    7. Top 5 Global Pharmaceutical Company Selects NewCardios QTinno for 2 Upcoming Phase I Drug Safety Trials
    8. Global Growth Factors ( Blood And Tissue ) Industry
    9. Global HPLC Systems & Accessories Industry
    10. Global Specialty Enzymes Industry
    11. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... NEW YORK , August 27, 2015 ... on enhancing image processing functions in the human vision system, ... Angeles point guard Chris Paul to ... basketball players who want to improve their real-life on-court performance. ... on the court, whether it is shooting a ball or ...
    (Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
    (Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
    (Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
    Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
    ... Pharmaceuticals, Inc ., a late-stage epigenetics oncology company, announced today that ... BIO Investor Forum , San Francisco, CA, ... on Target , Panel Discussion: HDACi and Their Progress in the ... Annual Healthcare Conference , New York, NY, November 16, 1:30 PM ...
    ... Metabolomx, a diagnostic company focused on breath analysis ... was awarded a Small Business Innovation Research (SBIR) contract ... combined Phase I/II Fast-Track contract will support the research ... lung cancer. Metabolomx, proprietary technology is designed ...
    ... 2011 Amsterdam Molecular Therapeutics (Euronext: AMT), ... today announced that the European Medicines Agency,s (EMA) Committee ... its earlier opinion that Glybera (alipogene tiparvovec) is not ... to the positive recommendation of CHMP Rapporteurs, the Scientific ...
    Cached Biology Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 3
    (Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
    (Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
    (Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
    Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
    ... a disease mechanism that links hereditary amyotrophic lateral sclerosis to ... to a possible therapeutic target. The findings are reported ... Neuroscience . ALS is an adult-onset disease that causes ... five years of diagnosis. Scott Brady, professor and ...
    ... Long-awaited advances in reducing the cost of certain ... quietly led to production of super-strong forms of the ... story of the current issue of Chemical & ... forms of polyethylene have led to availability of stronger, ...
    ... of cigarette smoke, tobacco companies have introduced "harm reduction ... But stem cell scientists at the University of California, ... off the tip of a cigarette) from harm reduction ... than sidestream smoke from a conventional brand. ...
    Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3Harm reduction cigarettes can be more harmful than conventional brands, researchers report 2
    Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
    Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
    Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
    ...
    Biology Products: